Safety and Efficacy of IDH1R132H-DC Vaccine in Gliomas
Not Applicable
- Conditions
- Glioma
- Interventions
- Biological: dendritic cells
- First Posted Date
- 2016-05-13
- Last Posted Date
- 2016-05-13
- Lead Sponsor
- Hebei Yanda Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT02771301
- Locations
- 🇨🇳
Beijing Tiantan Hospital, Beijing, Beijing, China
🇨🇳Hebei Yanda Hospital, Sanhe, Hebei, China
Ultra-low Dose Bevacizumab Plus Temozolomide for Recurrent High-grade Gliomas
Not Applicable
- Conditions
- Recurrent High-grade Glioma
- Interventions
- First Posted Date
- 2015-04-15
- Last Posted Date
- 2016-02-18
- Lead Sponsor
- Hebei Yanda Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT02416999
- Locations
- 🇨🇳
Hebei Yanda Hospital, Sanhe, Hebei, China
🇨🇳Beijing Tiantan Hospital, Beijing, Beijing, China
A Study to Evaluate the Safety and Effectiveness of PCV Chemotherapy in Patients With Recurrent High-grade Glioma With IDH1/2 Mutation
Not Applicable
- Conditions
- Recurrent High-grade Glioma
- Interventions
- Drug: Lomustine/Vincristine/Procarbazine
- First Posted Date
- 2015-01-07
- Last Posted Date
- 2015-04-09
- Lead Sponsor
- Hebei Yanda Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT02333513
- Locations
- 🇨🇳
Hebei Yanda Hospital, Sanhe, Hebei, China
🇨🇳Beijing Tiantan Hospital, Beijing, Beijing, China
© Copyright 2025. All Rights Reserved by MedPath